Name: Name:R7128
Brand: Angene
SKU: AG00GU5Y
Rating: 90 (10 reviews)

Catalog Number:

AG00GU5Y

Chemical Name:

R7128

CAS Number:

940908-79-2

Molecular Formula:

C18H26FN3O6

Molecular Weight:

399.4139

MDL Number:

MFCD22572932

IUPAC Name:

[(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate

InChI:

InChI=1S/C18H26FN3O6/c1-9(2)14(23)26-8-11-13(28-15(24)10(3)4)18(5,19)16(27-11)22-7-6-12(20)21-17(22)25/h6-7,9-11,13,16H,8H2,1-5H3,(H2,20,21,25)/t11-,13-,16-,18-/m1/s1

InChI Key:

MLESJYFEMSJZLZ-MAAOGQSESA-N

SMILES:

O=C(C(C)C)O[C@@H]1[C@@H](COC(=O)C(C)C)O[C@H]([C@]1(C)F)n1ccc(nc1=O)N

UNII:

TA63JX8X52

Complexity:

707

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

399.181g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

399.419g/mol

Monoisotopic Mass:

399.181g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

121A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

1.3

Title	Journal
The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.	Antimicrobial agents and chemotherapy 20140601
Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.	Antimicrobial agents and chemotherapy 20140501
Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.	Hepatology (Baltimore, Md.) 20140201
Tetrazole and triazole as bioisosteres of carboxylic acid: discovery of diketo tetrazoles and diketo triazoles as anti-HCV agents.	Bioorganic & medicinal chemistry letters 20130815
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).	Hepatology (Baltimore, Md.) 20120401
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.	Gastroenterology 20120401
Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase.	Antiviral therapy 20120101
The HCV NS5B nucleoside and non-nucleoside inhibitors.	Clinics in liver disease 20110801
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.	The Journal of infectious diseases 20101115
Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor.	Journal of pharmaceutical and biomedical analysis 20101102
Management of untreated and nonresponder patients with chronic hepatitis C.	Seminars in liver disease 20101101
Curing hepatitis C with pills: a step toward global control.	Lancet (London, England) 20101030
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.	Lancet (London, England) 20101030
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.	Journal of medicinal chemistry 20101014
Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.	Journal of medicinal chemistry 20090910